

Accepted Manuscript

Design, synthesis and evaluation of curcumin-based fluorescent probes to detect A β fibrils

Taki Sato, Mayumi Hotsumi, Koki Makabe, Hiroyuki Konno


PII: S0960-894X(18)30782-0
DOI: <https://doi.org/10.1016/j.bmcl.2018.10.002>
Reference: BMCL 26061

To appear in: *Bioorganic & Medicinal Chemistry Letters*

Received Date: 13 July 2018
Revised Date: 20 September 2018
Accepted Date: 1 October 2018

Please cite this article as: Sato, T., Hotsumi, M., Makabe, K., Konno, H., Design, synthesis and evaluation of curcumin-based fluorescent probes to detect A β fibrils, *Bioorganic & Medicinal Chemistry Letters* (2018), doi: <https://doi.org/10.1016/j.bmcl.2018.10.002>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Design, synthesis and evaluation of curcumin-based fluorescent probes to detect A β fibrils

Taki Sato, Mayumi Hotsumi, Koki Makabe, Hiroyuki Konno*

Department of Biological Engineering, Graduate School of Science and Technology,
Yamagata University, Yonezawa, Yamagata 992-8510, Japan.

Key words: Alzheimer's disease, Amyloid β , Curcumin, Inhibitor, Probe

Author information

*Corresponding author

Tel & FAX +81-238-26-3131

E-mail konno@yz.yamagata-u.ac.jp

ABSTRACT: Amyloid β fibrillation is an early event in Alzheimer's disease, so its detection is important to understand its roles in Alzheimer's disease. Curcumin, which has poor water solubility, has been reported to have many pharmacological activities including potent anti-amyloid β fibril activity in Alzheimer's disease. In this study, we found that curcumin analogues with the fluorescence property instead of non-inhibition of amyloid β fibrils. The development of new curcumin analogue, Me-CUR (9), as fluorescent switchable probe to detect amyloid β fibrils is described. Me-CUR (9) shows excellent fluorescence, especially higher than ThT (4), in the presence of amyloid β fibrils. These results suggest that Me-CUR (9) can become a useful *in vitro* amyloid fluorescence sensor for diagnosis of Alzheimer's disease.

Amyloid fibrils are insoluble aggregates with fibrillary morphology and a β -sheet rich structure that can cause several diseases known as amyloidosis due to their misfolding¹⁻³. Among the different amyloid-like peptides, those called amyloid β (A β) are very important because of their prominent role in Alzheimer's Disease (AD)^{4,5}. AD is a progressive neurodegenerative disorder characterized by cognitive decline, irreversible memory loss, disorientation and language impairment^{6,7}. One of the pathological hallmarks is the aggregation of A β peptide and its accumulation in the human brain has an important role in the etiology of AD⁸. Therefore, A β fibrils could be a biomarker for therapy or diagnosis for AD. Although there are several isoforms of A β species ranging in length from 39 to 43 residues, A β ₄₀ and A β ₄₂ are the most abundant (9:1 = A β ₄₀:A β ₄₂) and A β ₄₂ is more aggregation-prone⁹. Therefore, inhibiting or disrupting the A β ₄₂ aggregation process represents a promising therapeutic strategy for the prevention and treatment of AD.

Curcumin (CUR (1)), is a yellow pigment exacted from *Curcuma longa* (turmeric), which is commonly used as a food colorant, spice, and cosmetic, as well as a traditional medicine in Asian countries^{10,11}. In the last few decades, CUR (1) has become a research focus due to its numerous beneficial biological and pharmacological activities such as antioxidant, anti-tumor, anti-inflammatory and other desirable medicinal benefits¹²⁻¹⁷. CUR (1) is one of the PAINS (pan assay interference compounds) and IMPS (invalid metabolic compounds), and more than 1,000 curcuminoids have been developed to improve their activities to date¹⁸⁻²⁰. Especially, the effect of anti-A β fibrils as highly beneficial in the treatment of AD has been reported by the Ono group²¹. CUR (1) has a characteristic structure in which two phenolic groups are linked by an olefin chain containing a β -diketone moiety and the high crystallinity reduces the solubility to solvents markedly^{22,23}. Since the insolubility of CUR (1) in water may restrict its pharmacodynamics, we have successfully synthesized a water-soluble CUR analogue (Ws-CUR (2)), with potent inhibitory activity against A β fibrils. Ws-CUR (2) shows 31 μ M of water-solubility and has intensive inhibitory activity of A β fibrils²⁴.

To date, the most widely applied A β imaging probes have used positron emission tomography (PET) and single photon emission computed tomography (SPECT) using Congo Red (CR, (3)) and Thioflavin T (ThT (4))^{25,26}. CUR (1) has also been developed as a PET imaging dye or Near-infrared (NIR) dye; however, these imaging modalities

are hindered by their intrinsic high cost and time-consuming nature and result in patient exposure to radiation²⁷⁻²⁹. Therefore, labeling technology has been increasingly popular for imaging of A β fibrils as a potential alternative to other techniques^{30,31}. Among these molecular probes, ThT (4) is the most widely used dye for monitoring amyloid fibrils both *in vitro* and *in vivo*³². Although the ThT (4) binding model is largely unknown, the increasing emission intensity of ThT (4) upon binding to amyloid fibrils is due to the inhibition of the rotation around a single C-C bond in ThT (4)³³. Therefore, there is disadvantage in the point of low material selectivity. Moreover, CRANAD-2 (5) for NIR probe and Shiga-Y5 (6), ¹⁹F-MR diagnostic imaging probe, have the CUR-structure, so these results suggest that it is possible they can detect A β fibrils as a fluorescent molecular rotor to CUR (1)³⁴, which has five single C-C bonds. The property of CUR (1) is expected high selectivity and potent detection capability. In addition, most CUR (1) and its analogues were symmetry structures in the previous work by many researchers¹⁸⁻²⁰. Development of Ws-CUR (2) by our group indicated that asymmetry CUR structures exploit novel ability. Although a variety of organic dyes were reported, a few compounds have been applied as biomarker of A β fibrils. It is anticipated that CUR (1) and its analogues rarely show aggregation-induced emission (AIE) and can be reversibly showed AIE efficacy depending on the aggregation state of A β fibrils. Herein, we report the design, synthesis and evaluation of CUR analogues as new fluorescence probes (Figure 1).




Figure 1. Structure of CUR (1), Ws-CUR (2), CR (3), ThT (4), CRANAD-2 (5) and Shiga-Y5 (6)

In our previous work, we performed a structure activity relationship study (SAR) to develop an A β aggregation inhibitor. As depicted in Figure 2, inhibitory activity of

Me-CUR (7) against A β fibrils decreased markedly compared with those of Ws-CUR (2). In addition, ThT-induced fluorescence intensity of Me-CUR (7) with A β fibrils was more intense than that in the absence of CUR derivatives as a positive control (Figure 2).




Figure 2. Time-dependent fibril formation of A β 42 was monitored by ThT (4), Me-CUR (7) and Ws-CUR (2) (dye 5 μ M, A β 42 25 μ M).

As for this phenomenon, we assume that Me-CUR (7) has no inhibition activity for A β fibrils and may not induce their collapse. To investigate this phenomenon, we designed CUR analogues, which converted the hydroxy group into methoxy group of phenyl rings to develop more effective Me-CURs as fluorescence probes for A β fibrils. Moreover, Ws-CUR (2), which has an ortho hydroxy group, showed potent inhibition activity even though Ws-CUR (2) has one less hydroxy group than CUR (1). Therefore, we designed CUR analogues with two or three methoxy groups on their phenolic rings. Especially, the necessity for the methoxy group in the ortho-position of Me-CURs was verified to detect A β fibrils. Me-CURs (7) - (18) with four methoxy groups on their phenolic rings and a similar structure to CUR, were also investigated (Table 1). To prepare the designed compounds (7) - (18), aldol condensation of an acetylacetone-boron complex and benzaldehyde derivatives in the presence of piperidine or *n*-buthylamine is a key step (See supporting information SI-Scheme 1). Symmetrical derivatives were synthesized directly and asymmetric derivatives were synthesized twice by repeating the operation.





Table 1. Molecular design of Me-CURs.

OMe ^a	Compound	Ar1	Ar2
2	7	2	2
	8	3	3
3	9	3,4	2
	10	3,4	4
4	11	2,3	2,3
	12	2,3	2,5
	13	2,5	2,5
	14	3,4	2,3
	15	3,4	2,5
	16	3,4	3,4
	17	3,4,5	2
6	18	3,4,5	3,4,5

a: The number of methoxy groups.

a)



b)




Figure 3. (a) Fluorescence quantities of Me-CURs (7) - (18) for Aβ fibrils (Incubate time, 10h, ThT fluorescence, 100) (b) Time-dependent fibril formation of Aβ42 was monitored by ThT compared with 9 (dye 5 μM, Aβ42 25 μM).

Evaluation of synthesized molecules, Me-CURs (7) - (18), as fluorescence probes for Aβ fibrils was performed by an incubation assay with aggregated Aβ42 peptide. ThT (4), the control probe, is a benzothiazole dye that exhibits enhanced fluorescence upon

binding to amyloid fibrils. As shown in Figure 3a, fluorescence intensities of Me-CURs (**9**), (**15**) and (**16**) with the A β fibrils were stronger than those of ThT (**4**). In the spectra of the A β 42-ThT assay system in Figure 3b, **9** showed constant weak autofluorescence. In contrast, **9** behaved as selective light-up fluorescent probe upon binding to the A β fibrils, as fluorescence intensity was increasing. In other words, **9** can be selectively and reversibly turned on and off depending on the aggregation state of A β fibrils and act as an A β fibrils-responding On-Off switchable fluorescent probe (Figure 3).

To investigate the spacer unit of the CUR framework, “Downsizing” derivatives of Me-CUR (**9**), which have a short olefin linker and reduced number of ketones, were designed. Basically, the C7-diketone olefin linker of CUR framework was replaced with C5-diketone, C5-monoketone and C3-monoketone olefin linkers to afford downsized analogues (**19**), (**20**) and (**21**). These downsized analogues (**19**), (**20**) and (**21**) were synthesized as shown in SI-Scheme 2 (See supporting information SI-Scheme 2). A List-Barbas aldol reaction was employed to give C5-diketone derivatives (**19**) and C5-monoketone derivatives (**20**) as a key step. The downsizing analogue (**20**) was prepared by a base-catalyzed aldol condensation reaction starting from *o*-anis aldehyde. C3-monoketone derivatives (**21**) were synthesized by coupling of *o*-anis aldehyde and *o*-methoxy acetophenone in the presence of sodium methoxide. As shown in Figure 4, these short-linker Me-CURs (**19**), (**20**) and (**21**) showed weaker or undetectable fluorescence. The results suggested that the methoxy groups at the 3,4-positions of




Figure 4. “Downsizing” analogues of **9**; C5-diketone type derivative (**19**); C5-monoketone type derivative (**20**); C3-monoketone type derivative (**21**)

phenolic rings and olefin chain having both 7 carbon atoms and the β -diketone motif as CUR are needed to recognize the A β fibrils (Figure 4).

We also investigated the photophysical behavior of **9**, **15** and **16**. There was a significant association between the mechanism to stain A β fibrils and the molecular planarity as ThT (**4**) behaves like a “molecular rotor”. In detail, a low energy barrier allows the benzenamine and benzothiazole rings of ThT (**4**) to rotate freely about their shared C-C bond in solution. Amyloid fibrils are likely to present a ThT-binding site that sterically “locks” the bound dye, thus leading to enhancement of ThT fluorescence. Me-CURs also have the methoxy groups on phenyl rings, which are linked to the olefin chain via two single bonds. Thus, they feature high rotational flexibility and possess two different twisted intramolecular charge transfer (TICT) channels within the whole molecular structure. These intramolecular rotations lead to the non radiative deactivation of the fluorescent excited state, which could be another cause for the weak auto fluorescence of Me-CURs. To test this assumption, we investigated the effect of solvent viscosity on Me-CUR emission. The intramolecular rotation process is reported to be influenced by the viscosity of the medium; in a high viscosity medium, the intramolecular rotation was slowed down and hence enhanced the emission of Me-CURs (**9**), (**15**) and (**16**). Thus, we examined the viscosity effect on the emission behavior of Me-CURs (**9**), (**15**) and (**16**) which detected A β fibrils more sensitively than ThT (**4**) in glycerol. As shown in Figure 5b, the fluorescence intensity of Me-CURs (**9**), (**15**) and (**16**) were dramatically enhanced with a solvent viscosity which is typically observed for molecular rotors like ThT (**4**). These results support the fact that Me-CURs act as the molecular rotor and could turn on/off their emission when free rotation of phenyl rings to the olefin linker is restricted (Figure 5b). Based on this hypothesis, we calculated the molecular planarity of Me-CURs (**9**), (**15**) and (**16**) when the two carbon-carbon bonds sharing both sites of aromatic rings and the olefin linker of Me-CURs (**9**), (**15**) and (**16**) defined as their rotor (switch). As we expected, Me-CUR (**9**) had a high molecular planarity ($\Phi = 8.8$) compared with **15** ($\Phi = 79.3$) and **16** ($\Phi = 81.7$) (Figure 5a). Thus, the high molecular planarity of Me-CUR (**9**) is an important factor in the robust intense fluorescence when interacting with A β fibrils. Moreover, Me-CUR (**9**) showed sufficient Stokes shift to use as a fluorescence probe (Figure 5c).

The photoproperties of Me-CURs (**9**), (**15**) and (**16**) are shown in Figure 5c. To obtain more emission properties of Me-CUR (**9**), a concentration titration test was done. The fluorescence emission maxima of Me-CUR (**9**) shifted from 520 nm to 496 nm in the presence of A β fibrils from 0.5 μ M to 25 μ M as shown in Figure 5d. The concentration dependent-fluorescence spectral changes of Me-CUR (**9**) showed that the fluorescence intensity gradually increased along with increasing concentrations of A β fibrils, accompanied by a slight blue shift in λ_{max} , while it did not change markedly in the solution without A β fibrils (Figure 5). There is sigmoidal curve between fluorescence intensity shift (nm) and concentration of A β fibrils (μ M) and consequently, A β concentration at a range of 5-10 μ M prompts to a blue shift in λ_{ma} (See supporting information SI-Figure 2). As further investigation, the detection limit between A β fibrils and Me-CUR (**9**) was estimated on fluorescence intensity. To detect 25 μ M A β fibrils, Me-CUR (**9**) from 0.2 μ M to 500 μ M were attempted in standard condition. More than 10 μ M Me-CUR (**9**) gave saturated data (>60000 a.u.) and 0.2 μ M Me-CUR (**9**) shows no detection with 25 μ M A β fibrils. On the other hand, we confirmed that less than 6 nM A β fibrils was hardly performed fluorescent detection using 10 μ M Me-CUR (**9**) and, therefore, it needs to exist more than 60 nM A β fibrils to exhibit the ability of Me-CUR (**9**) (See supporting information SI-Figure 3).




Figure 5. (a) The most stable conformation of Me-CUR (9). (b) Viscosity-dependent emission behavior of Me-CUR (9), (15) and (16) were observed compared with ThT. (c) The absorption and emission spectra of Me-CUR (9). (d) Concentration dependent-fluorescence titration. Aβ42 0.5 - 25 μM, Me-CUR (9), 5 μM.

To observe the morphology of Aβ fibrils, the effect on amyloid formation was also investigated by TEM (Figure. 6a-f). Aβ42 formed amyloid fibrils of 30-120 nm diameter and 300 nm-2 μm long owing to aggregation properties (Figure 6a). The addition of ThT (4) to Aβ fibrils maintained the fibril formation as a positive control (Figure 6b). The addition of Me-CUR (9) kept the formation of fibrils from transforming and fibril formations of 300-500 nm in length were still observed, which corresponded to the fluorescence intensity (Figure 6c). In addition, the other Me-CUR analogues, which have short olefin linkers, C5-diketone type derivative (19), C5-monoketone type derivative (20), C3-monoketone type derivative (21) were also analyzed. The results indicated that the addition of the C5-diketone type derivative (19) led to some shorter fibril formation (~200 nm) (Figure 6d), and the addition of the C5-monoketone type derivative (20) and C3-monoketone (21) derivative changed the morphology of Aβ fibrils (Figure 6e,f). To visualize the interaction of ThT (4) or Me-CURs (9), (19)-(21)

with A β fibrils, we observed fibril formation by fluorescence microscopy (Figure 6g-l). A β fibrils showed no fluorescence with an excitation filter (B) of 460-495 nm as a negative control (Figure 6g). The fluorescence of ThT (**4**) was clearly evident on the amyloid aggregate and it showed as a green light (Figure 6h). We found that our promising probe, Me-CUR (**9**), stained the fibrous aggregates of A β fibrils with a yellow light (Figure 6i). Predictably, the C5-diketone type derivative (**19**) undetected the aggregates, and only confirmed their autofluorescence. Neither the C5-monoketone type derivative (**20**) nor the C3-monoketone type derivative (**21**) also showed any fluorescent activity to bind to the aggregates (Figure 6j-l).




Figure 6. TEM images of the A β fibrils (a-e). (a) A β fibrils. (b) the addition of ThT. (c) the addition of **9**. (d) the addition of **19**. (e) the addition of **20**. (f) the addition of **21**. Fluorescence microscopy analyses of the A β fibrils (g-l). (g) A β fibrils. (h) stained with ThT. (i) stained with **9**. (j) stained with **19**. (k) stained with **20**. (l) stained with **21**.

To predict insight into the possible interaction mechanism for A β fibrils binding, we performed molecular docking analysis. The binding mode of Me-CUR (**9**) or ThT (**4**) was achieved with A β fibrils using GOLD software on a 12-fold A β 1-42 fibril structure (PDB ID: 2MXU). As shown in Figure 7, Me-CUR (**9**) and ThT (**4**) located in the inner site of A β fibrils (Figure 7a,b). The binding mode between Me-CUR (**9**) or ThT (**4**) and the A β fibrils was mainly supported by the hydrophobic interaction. In detail, several significant binding interactions were observed within the docked complex, as depicted in Figure 7c,d. Our docking studies *in silico* further supported the fact that the localization site of Me-CUR (**9**) and ThT (**4**) are similar and are sustained by hydrophobic interaction and hydrogen bonding networks (Figure 7).




Figure 7. (a) Binding pose of ThT (4) in the A β fibrils; (b) Binding pose of 9 in the A β fibrils; (c) Detailed view of the docked ThT structure and the corresponding interacting amino-acid moieties within the binding site of A β fibrils; (d) Detailed view of the docked 9 structure and the corresponding interacting amino-acid moieties within the binding site of A β fibrils.

In summary, a new series of novel curcumin analogues, an Me-CUR library containing short linker moiety or various substituents, was successfully synthesized and evaluated as new imaging agents for A β fibrils. The Me-CURs, (9), (15), (16), which have a C7-diketone moiety and phenolic rings containing methoxy groups at 3,4-positions, showed higher fluorescence than ThT (4) as the most extensive amyloid sensor. Detailed spectroscopic studies indicated that Me-CUR (9) has high molecular planarity and thus it could strongly bind with the A β fibrils resulting in a large increase in its emission intensity with a large spectral shift. Me-CUR (9) is a fluorescent switchable probe to detect amyloid β fibrils with high sensitivity. At this time, Me-CUR (9) can be employed as the detecting agent of A β fibrils in vitro experiment instead of

ThT (4). These results suggest that Me-CUR (9) can become a useful fluorescence probe for diagnosis of AD. Our research using cell lines and a serum is in progress.

Supporting information

Additional experimental procedures, and analytical data for synthetic compounds. This material is available free of charge via the Internet at xxxxxxxx.

Acknowledgement

This work was supported in part by a Grant-in-Aid from the Japan Society for the Promotion of Science, KAKENHI (25450145) to H.K.

REFERENCES

1. Serpell CL. Alzheimer's amyloid fibrils: structure and assembly. *Biochem Biophys Acta*. 2013;1502:16-30.
2. Dobson MC. Protein folding and misfolding. *Nature* 2003;426:884–890.
3. Meyer-Luehmann M, Spires-jones LT, Prada C, Garcia-Alloza M, de Caligon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model. *Nature* 2008;451:7204.
4. Games D, Adams D, Alessanderini R, Barbour R, Berthette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. *Nature* 1995;373:523-527.
5. Haass C, Hung AY, Schlossmacher MG, Oltersdorf T, Teplow DB, Selkoe DJ. Normal cellular processing of the beta-amyloid precursor protein results in the secretion of the amyloid beta peptide and related molecules. *Ann N Y Acad Sci*. 1993;695:109-116.
6. Burns A, Iliffe S. Alzheimer's disease. *Biol Mol J*. 2009;338:b158.
7. Hardy J, Selkoe JD. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* 2002;297:353-356.
8. Selkoe JD. Alzheimer's disease: genes, proteins, and therapy. *Physiol Rev*. 2001;81:741-766.
9. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. *Lancet* 2006;368:387- 403.
10. Fabricant SD, Farnsworth RN. The value of plants used in traditional medicine for drug discovery. *Environmental Health Perspectives*. 2001;109:69-75.


11. Ammon PTH, Wahl AM. Pharmacology of *Curcuma longa*. *Planta Med.* 1991;57:1-7.
12. Masuda T, Hidaka K, Shinohara A, Yamaguchi H. Chemical studies on antioxidant mechanism of curcuminoid: analysis of radical reaction products from curcumin. *J Agric Food Chem.* 1999;47:71-77.
13. Shishodia S, Sethi G, Aggarwal BB. Curcumin getting back to the roots. *Ann N Y Acad Sci.* 2005;1056:206-217.
14. Siwak RD, Shishodia S, Aggarwal BB, Kurzrock R. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. *Cancer* 2005;104:879-890.
15. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, Price JE. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. *Clin Cancer Res.* 2005;11:7490-9498.
16. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaB kinase and Akt activation. *Mol Pharmacol.* 2006;69:195-206.
17. Mukhopadhyay A, Basu N, Ghatak N, Gujral KP. Anti-inflammatory and irritant activities of curcumin analogues in rats. *Agents and Actions* 1982;12:4.
18. Baell BJ, Holloway AG. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. *J Med Chem.* 2010;53:2719-2740.
19. Bisson J, McAlpine JB, Friesen JB, Chen S-N, Graham J, Pauli GF. Can Invalid Bioactives Undermine Natural Product-Based Drug Discovery? *J Med Chem.* 2016;59: 1671-1690.
20. Nelson MK, Dahlin LJ, Bisson J, Graham J, Pauli FG, Walter AM. The essential medicinal chemistry of curcumin. *J Med Chem.* 2017;60: 1620-1637.
21. Ono K, Hasegawa K. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. *Neurosci Res.* 2004;75:742-750.
22. Payton-Stewart F, Sandasky P, Alworth W. NMR Study of the Solution Structure of Curcumin. *J Nat Prod.* 2007;70:143-146.
23. Anand P, Kunnumakkara BA, Newman AR, Aggarwal BB. Bioavailability of curcumin: problems and promises. *Mol Pharm.* 2007;4:807-818.
24. Endo H, Nikaido Y, Nakadate M, Ise S, Konno H. Structure activity relationship study of curcumin analogues toward the amyloid-beta aggregation inhibitor. *Bioorg Med Chem Lett.* 2014;24:5621-5626.

25. Mathis AC, Bacskai JB, Kajdasz TS, McLellan EM, Froach PM, Hyman TB, Holt PD, Wang Y, Huang GF, Debnath LM, Klunk EW. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. *Bioorg Med Chem Lett*. 2002;12:295-298.
26. Nordberg A. PET imaging of amyloid in Alzheimer's Disease. *Lancet Neurol*. 2004;3:519-927.
27. Ryu KE, Choe SY, Lee KH, Choi Y, Kim TB. Curcumin and dehydrozingerone Derivatives: synthesis, radiolabeling, and evaluation for β -amyloid plaque imaging. *J Med Chem*. 2006;49:6111-6119.
28. Ran C, Xu X, Raymond SR, Ferrara JB, Neal K, Bacskai JB, Medarova Z, Moore A. Design, synthesis, and testing of difluoroboron-derivatized curcumins as near-infrared probes for in vivo detection of amyloid- β deposits. *J Am Chem Soc*. 2009;131:15257-15261.
29. Brix G, Lechel U, Glatting G, Ziegler IS, Munzing W, Muller PS, Beyer T. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. *J Nucl Med*. 2005;46:608-613.
30. Johnson AK, Fox CN, Sperling AR, Klunk EWJ. Brain imaging in Alzheimer's disease. *Cold Spring Harb Perspect Med*. 2012;2:a006213.
31. Zhang Z, Sohgewa M, Yamashita K, Noda M. Real-time characterization of fibrillization process of amyloid-beta on phospholipid membrane using a new label-free detection technique based on a cantilever-based liposome biosensor. *Sensors and Actuators* 2006;236:893-899.
32. Hudson SH, Ecroyd H, Kee WT, Carver AJ. The thioflavin T fluorescence assay for amyloid fibril detection can be biased by the presence of exogenous compounds. *FEBS Journal* 2009;276:5960-5972.
33. Biancalana M, Koide S. Molecular mechanism of Thioflavin-T binding to amyloid fibrils. *Biochim Biophys Acta*. 2010;1804:1405-1412.
34. Toyama I, Yanagisawa D, Taguchi H, Kato T, Hirao K, Shirai N, Sogabe T, Ibrahim NF, Inubushi T, Morikawa S. Amyloid imaging using fluorine-19 magnetic resonance imaging ((¹⁹F)-MRI). *Ageing Res Rev*. 2016;30:85-94.

Design, synthesis and evaluation of curcumin-based fluorescent probes to detect A β fibrils

Taki Sato, Mayumi Hotsumi, Koki Makabe, Hiroyuki Konno*

Graduate School of Science and Technology, Yamagata University



Design, synthesis and evaluation of curcumin-based fluorescent probes to detect A β fibrils

Taki Sato, Mayumi Hotsumi, Koki Makabe, Hiroyuki Konno*

Department of Biological Engineering, Graduate School of Science and Technology,
Yamagata University, Yonezawa, Yamagata 992-8510, Japan.

Highlights:

Me-CUR is a fluorescent switchable probe to detect amyloid β fibrils with high sensitivity

Me-CUR can be employed as the detecting agent of A β fibrils in vitro experiment instead of ThT

Me-CUR has high molecular planarity and thus it could strongly bind with the A β fibrils